This is an exploratory investigation of safety, pharmacokinetic (PK) and pharmacodynamic (PD)
effects of BAY59-7939 with multiple oral doses of 10 mg, 15 mg and 20 mg once daily (od) in
Japanese subjects with non-valvular atrial fibrillation (originally described in Japanese).